Skip to main content

Advertisement

SpringerLink
Log in

Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing

  • Review
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

Thyroid carcinoma (TC) is a rare neoplasia of the endocrine system and account for about 2–3% of all human tumors. According to their cell origin and histological features, different histotypes of thyroid carcinoma are described. Genetic alterations involved in the pathogenesis of thyroid cancer have been described and it has been shown that alterations of the RET gene are common events in all TC hystotypes. Aim of this review is to give an overview of the relevance of RET alterations in TC and to provide indications, timing and methodologies, for RET genetic analysis.

Methods

A revision of the literature has been performed and indications for the experimental approach for the RET analysis have been reported.

Conclusions

The analysis of RET mutations in TC has a very important clinical relevance for the early diagnosis of the hereditary forms of MTC, for the follow-up of TC patients and for the identification of those cases that can benefit from a specific treatment able to inhibit the effect of mutated RET.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. C. Romei, E. Pardi, F. Cetani, R. Elisei, Genetic and clinical features of multiple endocrine neoplasia types 1 and 2. J. Oncol. 2012, 705036 (2012)

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Cancer Genome Atlas Research Network, Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676–690 (2014)

    Google Scholar 

  3. R. Ciampi, C. Romei, T. Ramone, A. Prete, A. Tacito, V. Cappagli, V. Bottici, D. Viola, L. Torregrossa, C. Ugolini, F. Basolo, R. Elisei, Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing. IScience 20, 324–336 (2019)

    CAS  PubMed  PubMed Central  Google Scholar 

  4. I. Landa, T. Ibrahimpasic, L. Boucai, R. Sinha, J.A. Knauf, R.H. Shah, S. Dogan, J.C. Ricarte-Filho, G.P. Krishnamoorthy, B. Xu, N. Schultz, M.F. Berger, C. Sander, B.S. Taylor, R. Ghossein, I. Ganly, J.A. Fagin, Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Investig. 126, 1052–1066 (2016)

    PubMed  PubMed Central  Google Scholar 

  5. C. Romei, R. Elisei, A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer. Int J. Mol. Sci. 22, 1726 (2021)

    CAS  PubMed  PubMed Central  Google Scholar 

  6. L. Valerio, L. Pieruzzi, C. Giani, L. Agate, V. Bottici, L. Lorusso, V. Cappagli, L. Puleo, A. Matrone, D. Viola, C. Romei, R. Ciampi, E. Molinaro, R. Elisei, Targeted Therapy in Thyroid Cancer: State of the Art. Clin. Oncol. 29, 316–324 (2017)

    CAS  Google Scholar 

  7. E. Arighi, M.G. Borrello, H. Sariola, RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 16, 441–467 (2005)

    CAS  PubMed  Google Scholar 

  8. K. Kawai, M. Takahashi, Intracellular RET signaling pathways activated by GDNF. Cell Tissue Res. 382, 113–123 (2020)

    CAS  PubMed  Google Scholar 

  9. A. Cerrato, V. De Falco, M. Santoro, Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J. Mol. Endocrinol. 43, 143–155 (2009)

    CAS  PubMed  Google Scholar 

  10. M. Santoro, R.M. Melillo, F. Carlomagno, A. Fusco, G. Vecchio, Molecular mechanisms of RET activation in human cancer. Ann. N. Y Acad. Sci. 963, 116–121 (2002)

    CAS  PubMed  Google Scholar 

  11. R. Elisei, A. Tacito, T. Ramone, R. Ciampi, V. Bottici, V. Cappagli, D. Viola, A. Matrone, L. Lorusso, L. Valerio, C. Giani, C. Campopiano, A. Prete, L. Agate, E. Molinaro, C. Romei, Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations. Genes (Basel) 10, 698 (2019)

    CAS  PubMed  Google Scholar 

  12. F. Raue, K. Frank-Raue, Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid Carcinoma. J. Endocr. Soc. 2, 933–943 (2018)

    CAS  PubMed  PubMed Central  Google Scholar 

  13. L.M. Mulligan, RET revisited: expanding the oncogenic portfolio. Nat. Rev. Cancer 14, 173–186 (2014)

    CAS  PubMed  Google Scholar 

  14. S.A. Wells, Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors. Endocr. Relat. Cancer 25, T1 (2018)

    PubMed  Google Scholar 

  15. C. Romei, R. Ciampi, R. Elisei, A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat. Rev. Endocrinol. 12, 192–202 (2016)

    CAS  PubMed  Google Scholar 

  16. L.M. Mulligan, J.B.J. Kwok, C.S. Healey, M.J. Elsdon, C. Eng, E. Gardner, D.R. Love, S.E. Mole, J.K. Moore, L. Papi, M.A. Ponder, H. Telenius, A. Tunnacliffe, B.A.J. Ponder, Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363, 458–460 (1993)

    CAS  PubMed  Google Scholar 

  17. O. Gimm, D.J. Marsh, S.D. Andrew, A. Frilling, P.L. Dahia, L.M. Mulligan, J.D. Zajac, B.G. Robinson, C. Eng, Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J. Clin. Endocrinol. Metab. 82, 3902–3904 (1997)

    CAS  PubMed  Google Scholar 

  18. F. Castinetti, S.G. Waguespack, A. Machens, S. Uchino, K. Hasse-Lazar, G. Sanso, T. Else, S. Dvorakova, X.P. Qi, R. Elisei, A.L. Maia, J. Glod, D.M. Lourenço, N. Valdes, J. Mathiesen, N. Wohllk, T.R. Bandgar, D. Drui, M. Korbonits, M.R. Druce, C. Brain, T. Kurzawinski, A. Patocs, M.J. Bugalho, A. Lacroix, P. Caron, P. Fainstein-Day, F. Borson Chazot, M. Klein, T.P. Links, C. Letizia, L. Fugazzola, O. Chabre, L. Canu, R. Cohen, A. Tabarin, A. Spehar Uroic, D. Maiter, S. Laboureau, C. Mian, M. Peczkowska, F. Sebag, T. Brue, D. Mirebeau-Prunier, L. Leclerc, B. Bausch, A. Berdelou, A. Sukurai, P. Vlcek, J. Krajewska, M. Barontini, C. Vaz Ferreira Vargas, L. Valerio, L. Ceolin, S. Akshintala, A. Hoff, C. Godballe, B. Jarzab, C. Jimenez, C. Eng, T. Imai, M. Schlumberger, E. Grubbs, H. Dralle, H.P. Neumann, E. Baudin, Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes Endocrinol. 7, 213–220 (2019)

    PubMed  PubMed Central  Google Scholar 

  19. D.K. Crockett, S.R. Piccolo, P.G. Ridge, R.L. Margraf, E. Lyon, M.S. Williams, J.A. Mitchell, Predicting phenotypic severity of uncertain gene variants in the RET proto-oncogene. PLoS ONE 6, e18380 (2011)

    CAS  PubMed  PubMed Central  Google Scholar 

  20. B. Cosci, A. Vivaldi, C. Romei, F. Gemignani, S. Landi, R. Ciampi, A. Tacito, E. Molinaro, L. Agate, V. Bottici, V. Cappagli, D. Viola, P. Piaggi, P. Vitti, A. Pinchera, R. Elisei, In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. Endocr. Relat. Cancer 18, 603–612 (2011)

    CAS  PubMed  Google Scholar 

  21. R.L. Margraf, D.K. Crockett, P.M.F. Krautscheid, R. Seamons, F.R.O. Calderon, C.T. Wittwer, R. Mao, Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. Hum. Mutat. 30, 548–556 (2009)

    CAS  PubMed  Google Scholar 

  22. C. Romei, B. Cosci, G. Renzini, V. Bottici, E. Molinaro, L. Agate, P. Passannanti, D. Viola, A. Biagini, F. Basolo, C. Ugolini, G. Materazzi, A. Pinchera, P. Vitti, R. Elisei, RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clin. Endocrinol. (Oxf.) 74, 241–247 (2011)

    CAS  PubMed  Google Scholar 

  23. R. Elisei, R. Ciampi, A. Matrone, A. Prete, C. Gambale, T. Ramone, G. Simeakis, G. Materazzi, L. Torregrossa, C. Ugolini, C. Romei, Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib. J. Clin. Endocrinol. Metab. 107, 2195–2202 (2022)

    PubMed  Google Scholar 

  24. C. Romei, F. Casella, A. Tacito, V. Bottici, L. Valerio, D. Viola, V. Cappagli, A. Matrone, R. Ciampi, P. Piaggi, C. Ugolini, L. Torregrossa, F. Basolo, G. Materazzi, P. Vitti, R. Elisei, New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations. J. Med. Genet. 53, 729–734 (2016)

    CAS  PubMed  Google Scholar 

  25. C. Mian, G. Pennelli, S. Barollo, E. Cavedon, D. Nacamulli, F. Vianello, I. Negro, G. Pozza, I.M. Boschin, M.R. Pelizzo, M. Rugge, F. Mantero, M.E. Girelli, G. Opocher, Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur. J. Endocrinol. 164, 971–976 (2011)

    CAS  PubMed  Google Scholar 

  26. M.M. Moura, B.M. Cavaco, A.E. Pinto, R. Domingues, J.R. Santos, M.O. Cid, M.J. Bugalho, V. Leite, Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br. J. Cancer 100, 1777–1783 (2009)

    CAS  PubMed  PubMed Central  Google Scholar 

  27. R. Elisei, B. Cosci, C. Romei, V. Bottici, G. Renzini, E. Molinaro, L. Agate, A. Vivaldi, P. Faviana, F. Basolo, P. Miccoli, P. Berti, F. Pacini, A. Pinchera, Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J. Clin. Endocrinol. Metab. 93, 682–687 (2008)

    CAS  PubMed  Google Scholar 

  28. T. Ramone, C. Mulè, R. Ciampi, V. Bottici, V. Cappagli, A. Prete, A. Matrone, P. Piaggi, L. Torregrossa, F. Basolo, R. Elisei, C. Romei, RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency. Genes (Basel) 12, 35 (2020)

    PubMed  Google Scholar 

  29. C. Mulè, R. Ciampi, T. Ramone, A. Prete, A. Matrone, V. Cappagli, L. Torregrossa, F. Basolo, R. Elisei, C. Romei, Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma. Biomolecules 11, 1542 (2021)

    PubMed  PubMed Central  Google Scholar 

  30. M. Santoro, M. Moccia, G. Federico, F. Carlomagno, RET Gene Fusions in Malignancies of the Thyroid and Other Tissues. Genes (Basel) 11, 424 (2020)

    CAS  PubMed  Google Scholar 

  31. R. Elisei, C. Romei, T. Vorontsova, B. Cosci, V. Veremeychik, E. Kuchinskaya, F. Basolo, E.P. Demidchik, P. Miccoli, A. Pinchera, F. Pacini, RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J. Clin. Endocrinol. Metab. 86, 3211–3216 (2001)

    CAS  PubMed  Google Scholar 

  32. Y.E. Nikiforov, J.M. Rowland, K.E. Bove, H. Monforte-Munoz, J.A. Fagin, Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 57, 1690–1694 (1997)

    CAS  PubMed  Google Scholar 

  33. A.G. Saad, S. Kumar, E. Ron, J.H. Lubin, J. Stanek, K.E. Bove, Y.E. Nikiforov, Proliferative activity of human thyroid cells in various age groups and its correlation with the risk of thyroid cancer after radiation exposure. J. Clin. Endocrinol. Metab. 91, 2672–2677 (2006)

    CAS  PubMed  Google Scholar 

  34. O.M. Sheils, J.J. O’eary, V. Uhlmann, K. Lättich, E.C. Sweeney, ret/PTC-1 Activation in Hashimoto Thyroiditis. Int J. Surg. Pathol. 8, 185–189 (2000)

    CAS  PubMed  Google Scholar 

  35. B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1–133 (2016)

    PubMed  PubMed Central  Google Scholar 

  36. Y.E. Nikiforov, L.A. Erickson, M.N. Nikiforova, C.M. Caudill, R.V. Lloyd, Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am. J. Surg. Pathol. 25, 1478–1484 (2001)

    CAS  PubMed  Google Scholar 

  37. L. Højer Wang, M. Wehland, P.M. Wise, M. Infanger, D. Grimm, M.C. Kreissl, Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect. Int J. Mol. Sci. 24, 2312 (2023)

    PubMed  PubMed Central  Google Scholar 

  38. S.A. Wells, B.G. Robinson, R.F. Gagel, H. Dralle, J.A. Fagin, M. Santoro, E. Baudin, R. Elisei, B. Jarzab, J.R. Vasselli, J. Read, P. Langmuir, A.J. Ryan, M.J. Schlumberger, Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 30, 134–141 (2012)

    CAS  PubMed  Google Scholar 

  39. R. Elisei, M.J. Schlumberger, S.P. Müller, P. Schöffski, M.S. Brose, M.H. Shah, L. Licitra, B. Jarzab, V. Medvedev, M.C. Kreissl, B. Niederle, E.E.W. Cohen, L.J. Wirth, H. Ali, C. Hessel, Y. Yaron, D. Ball, B. Nelkin, S.I. Sherman, Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol. 31, 3639–3646 (2013)

    CAS  PubMed  PubMed Central  Google Scholar 

  40. M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.-B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, N. Engl. J. Med. 372, 621–630 (2015)

    PubMed  Google Scholar 

  41. M.S. Brose, C.M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt, C. de la Fouchardiere, F. Pacini, R. Paschke, Y.K. Shong, S.I. Sherman, J.W.A. Smit, J. Chung, C. Kappeler, C. Peña, I. Molnár, M.J. Schlumberger, and DECISION investigators. Lancet 384, 319–328 (2014)

    CAS  PubMed  PubMed Central  Google Scholar 

  42. V. Subbiah, V. Velcheti, B.B. Tuch, K. Ebata, N.L. Busaidy, M.E. Cabanillas, L.J. Wirth, S. Stock, S. Smith, V. Lauriault, S. Corsi-Travali, D. Henry, M. Burkard, R. Hamor, K. Bouhana, S. Winski, R.D. Wallace, D. Hartley, S. Rhodes, M. Reddy, B.J. Brandhuber, S. Andrews, S.M. Rothenberg, A. Drilon, Selective RET kinase inhibition for patients with RET-altered cancers. Ann. Oncol. 29, 1869–1876 (2018)

    CAS  PubMed  PubMed Central  Google Scholar 

  43. V. Subbiah, J.F. Gainor, R. Rahal, J.D. Brubaker, J.L. Kim, M. Maynard, W. Hu, Q. Cao, M.P. Sheets, D. Wilson, K.J. Wilson, L. DiPietro, P. Fleming, M. Palmer, M.I. Hu, L. Wirth, M.S. Brose, S.-H.I. Ou, M. Taylor, E. Garralda, S. Miller, B. Wolf, C. Lengauer, T. Guzi, E.K. Evans, Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Disco. 8, 836–849 (2018)

    CAS  Google Scholar 

  44. L.J. Wirth, M.S. Brose, R. Elisei, J. Capdevila, A.O. Hoff, M.I. Hu, M. Tahara, B. Robinson, M. Gao, M. Xia, P. Maeda, E. Sherman, LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer. Future Oncol. 18, 3143–3150 (2022)

    CAS  PubMed  Google Scholar 

  45. V. Subbiah, M.I. Hu, L.J. Wirth, M. Schuler, A.S. Mansfield, G. Curigliano, M.S. Brose, V.W. Zhu, S. Leboulleux, D.W. Bowles, C.S. Baik, D. Adkins, B. Keam, I. Matos, E. Garralda, J.F. Gainor, G. Lopes, C.-C. Lin, Y. Godbert, D. Sarker, S.G. Miller, C. Clifford, H. Zhang, C.D. Turner, M.H. Taylor, Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 9, 491–501 (2021)

    CAS  PubMed  Google Scholar 

  46. S. Filetti, C. Durante, D.M. Hartl, S. Leboulleux, L.D. Locati, K. Newbold, M.G. Papotti, A. Berruti; and ESMO Guidelines Committee, Electronic address: clinicalguidelines@esmo.org. Ann. Oncol. 33, 674–684 (2022)

    CAS  PubMed  Google Scholar 

  47. A. Prete, A. Matrone, C. Gambale, V. Bottici, V. Cappagli, C. Romei, L. Torregrossa, L. Valerio, E. Minaldi, M.C. Campopiano, L. Lorusso, L. Agate, E. Molinaro, D. Viola, T. Ramone, C. Mulè, R. Ciampi, F. Basolo, R. Elisei, Active Surveillance in RET Gene Carriers Belonging to Families with Multiple Endocrine Neoplasia. Cancers (Basel) 13, 5554 (2021)

    CAS  PubMed  Google Scholar 

  48. R. Elisei, M. Alevizaki, B. Conte-Devolx, K. Frank-Raue, V. Leite, G.R. Williams, 2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur. Thyroid J. 1, 216–231 (2013)

    CAS  PubMed  Google Scholar 

  49. M. Wiench, Z. Wygoda, E. Gubala, J. Wloch, K. Lisowska, J. Krassowski, D. Scieglinska, A. Fiszer-Kierzkowska, D. Lange, D. Kula, M. Zeman, J. Roskosz, A. Kukulska, Z. Krawczyk, B. Jarzab, Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J. Clin. Oncol. 19, 1374–1380 (2001)

    CAS  PubMed  Google Scholar 

  50. N.A. Frisco, A.H. Gunn, S.M. Thomas, M.T. Stang, R.P. Scheri, H.S. Kazaure, Medullary thyroid cancer with RET V804M mutation: more indolent than expected? Surgery 173, 260–267 (2023)

    PubMed  Google Scholar 

  51. S.A. Wells, S.L. Asa, H. Dralle, R. Elisei, D.B. Evans, R.F. Gagel, N. Lee, A. Machens, J.F. Moley, F. Pacini, F. Raue, K. Frank-Raue, B. Robinson, M.S. Rosenthal, M. Santoro, M. Schlumberger, M. Shah, S.G. Waguespack, and American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Thyroid 25, 567–610 (2015)

    PubMed  PubMed Central  Google Scholar 

  52. W.A. Faucett, H. Peay, C.R. Coughlin, Genetic Testing: Consent and Result Disclosure for Primary Care Providers. Med. Clin. North Am. 103, 967–976 (2019)

    PubMed  PubMed Central  Google Scholar 

  53. A. Kotwal, D. Erickson, J.R. Geske, I.D. Hay, M.R. Castro, Predicting Outcomes in Sporadic and Hereditary Medullary Thyroid Carcinoma over Two Decades. Thyroid 31, 616–626 (2021)

    CAS  PubMed  Google Scholar 

  54. O. Twito, S. Grozinsky-Glasberg, S. Levy, G. Bachar, D.J. Gross, C. Benbassat, A. Rozental, D. Hirsch, Clinico-pathologic and dynamic prognostic factors in sporadic and familial medullary thyroid carcinoma: an Israeli multi-center study. Eur. J. Endocrinol. 181, 13–21 (2019)

    CAS  PubMed  Google Scholar 

  55. H. Gharib, W.M. McConahey, R.D. Tiegs, E.J. Bergstralh, J.R. Goellner, C.S. Grant, J.A. van Heerden, G.W. Sizemore, I.D. Hay, Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clin. Proc. 67, 934–940 (1992)

    CAS  PubMed  Google Scholar 

  56. X.H. Gao, J. Li, H.F. Gong, G.Y. Yu, P. Liu, L.Q. Hao, L.J. Liu, C.G. Bai, W. Zhang, Comparison of Fresh Frozen Tissue With Formalin-Fixed Paraffin-Embedded Tissue for Mutation Analysis Using a Multi-Gene Panel in Patients With Colorectal Cancer. Front. Oncol. 10, 310 (2020)

    PubMed  PubMed Central  Google Scholar 

  57. A. Armakolas, M. Kotsari, J. Koskinas, Liquid Biopsies, Novel Approaches and Future Directions. Cancers (Basel) 15, 1579 (2023)

    CAS  PubMed  Google Scholar 

  58. A.A. Wijewardene, M. Chehade, M.L. Gild, R.J. Clifton-Bligh, M. Bullock, Translational Utility of Liquid Biopsies in Thyroid Cancer Management. Cancers (Basel) 13, 3443 (2021)

    PubMed  Google Scholar 

  59. R. Ciampi, C. Romei, T. Ramone, A. Matrone, A. Prete, C. Gambale, G. Materazzi, L. De Napoli, L. Torregrossa, F. Basolo, M.G. Castagna, L. Brilli, E. Ferretti, R. Elisei, Pre- and Post-operative Circulating Tumoral DNA in Patients With Medullary Thyroid Carcinoma. J. Clin. Endocrinol. Metab. 107, e3420 (2022)

    PubMed  Google Scholar 

  60. Y. Seki, T. Yoshida, T. Kohno, K. Masuda, Y. Okuma, Y. Goto, H. Horinouchi, N. Yamamoto, K. Kuwano, Y. Ohe, Liquid biopsy for the detection of resistance mutations to ROS1 and RET inhibitors in non-small lung cancers: A case series study. Respir. Investig. 60, 852–856 (2022)

    CAS  PubMed  Google Scholar 

  61. J.-M. Rey, V. Ducros, P. Pujol, Q. Wang, M.-P. Buisine, H. Aissaoui, T. Maudelonde, S. Olschwang, Improving Mutation Screening in Patients with Colorectal Cancer Predisposition Using Next-Generation Sequencing. J. Mol. Diagn. 19, 589–601 (2017)

    CAS  PubMed  Google Scholar 

  62. D. Zou, W. Ye, L.M. Hess, N.R. Bhandari, A. Ale-Ali, J. Foster, P. Quon, M. Harris, Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small-Cell Lung Cancer in the United States. J. Mol. Diagn. 24, 901–914 (2022)

    CAS  PubMed  Google Scholar 

  63. L. Enewold, K. Zhu, E. Ron, A.J. Marrogi, A. Stojadinovic, G.E. Peoples, S.S. Devesa, Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol. Biomark. Prev. 18, 784–791 (2009)

    Google Scholar 

  64. M.J. Schlumberger, Papillary and follicular thyroid carcinoma. N. Engl. J. Med. 338, 297–306 (1998)

    CAS  PubMed  Google Scholar 

  65. M. Xing, A.S. Alzahrani, K.A. Carson, Y.K. Shong, T.Y. Kim, D. Viola, R. Elisei, B. Bendlová, L. Yip, C. Mian, F. Vianello, R.M. Tuttle, E. Robenshtok, J.A. Fagin, E. Puxeddu, L. Fugazzola, A. Czarniecka, B. Jarzab, C.J. O’Neill, M.S. Sywak, A.K. Lam, G. Riesco-Eizaguirre, P. Santisteban, H. Nakayama, R. Clifton-Bligh, G. Tallini, E.H. Holt, V. Sýkorová, Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. JCO 33, 42–50 (2015)

    Google Scholar 

  66. R. Elisei, D. Viola, L. Torregrossa, R. Giannini, C. Romei, C. Ugolini, E. Molinaro, L. Agate, A. Biagini, C. Lupi, L. Valerio, G. Materazzi, P. Miccoli, P. Piaggi, A. Pinchera, P. Vitti, F. Basolo, The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J. Clin. Endocrinol. Metab. 97, 4390–4398 (2012)

    CAS  PubMed  Google Scholar 

  67. I. Letovanec, S. Finn, P. Zygoura, P. Smyth, A. Soltermann, L. Bubendorf, E.-J. Speel, A. Marchetti, D. Nonaka, K. Monkhorst, H. Hager, M. Martorell, A. Sejda, R. Cheney, J. Hernandez-Losa, E. Verbeken, W. Weder, S. Savic, A. Di Lorito, A. Navarro, E. Felip, A. Warth, P. Baas, P. Meldgaard, F. Blackhall, A.-M. Dingemans, H. Dienemann, R. Dziadziuszko, J. Vansteenkiste, C. O’Brien, T. Geiger, J. Sherlock, J. Schageman, U. Dafni, R. Kammler, K. Kerr, E. Thunnissen, R. Stahel, S. Peters, and European Thoracic Oncology Platform Lungscape Consortium. J. Thorac. Oncol. 13, 413–425 (2018)

    CAS  PubMed  Google Scholar 

  68. T.J. Musholt, J.I. Staubitz, R.J. Antonio Cámara, P.B. Musholt, D. Humberg, E. Springer, A. Schad, Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis. Eur. J. Surg. Oncol. 45, 1018–1024 (2019)

    PubMed  Google Scholar 

  69. C. Belli, F. Penault-Llorca, M. Ladanyi, N. Normanno, J.-Y. Scoazec, L. Lacroix, J.S. Reis-Filho, V. Subbiah, J.F. Gainor, V. Endris, M. Repetto, A. Drilon, A. Scarpa, F. André, J.-Y. Douillard, G. Curigliano, ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann. Oncol. 32, 337–350 (2021)

    CAS  PubMed  Google Scholar 

  70. S. Dutta, S. Tarafdar, P. Mukhopadhyay, N.P. Bhattacharyya, S. Ghosh, Detection of driver mutations in plasma cell-free nucleic acids in differentiated thyroid neoplasm. Eur. J. Endocrinol. 188, lvac018 (2023)

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Endocrinology, Department of Clinical and Experimental Medicine, University-Hospital of Pisa, 56124, Pisa, Italy

    Rossella Elisei & Cristina Romei

Authors
  1. Rossella Elisei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristina Romei
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Both authors equally contributed to the drafting and editing of the paper.

Corresponding author

Correspondence to Rossella Elisei.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elisei, R., Romei, C. Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing. Endocrine 81, 206–215 (2023). https://doi.org/10.1007/s12020-023-03368-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-023-03368-w

Keywords

Search

Navigation